These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8289134)

  • 1. Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine.
    Ingwersen SH; Snel S; Mant TG; Edwards D
    J Pharm Sci; 1993 Nov; 82(11):1164-6. PubMed ID: 8289134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.
    Søgaard U; Michalow J; Butler B; Lund Laursen A; Ingersen SH; Skrumsager BK; Rafaelsen OJ
    Int Clin Psychopharmacol; 1990 Oct; 5(4):237-51. PubMed ID: 2150527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food intake increases the relative oral bioavailability of vanoxerine.
    Ingwersen SH; Mant TG; Larsen JJ
    Br J Clin Pharmacol; 1993 Mar; 35(3):308-10. PubMed ID: 8471409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909.
    Nielsen-Kudsk F; Siggaard C; Nielsen CB; Mellemkjaer S
    Pharmacol Toxicol; 1990 Mar; 66(3):197-202. PubMed ID: 2139724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Column liquid chromatographic assay of the dopamine reuptake inhibitor vanoxerine (GBR 12909) in human serum.
    Ingwersen SH
    J Chromatogr; 1991 Nov; 571(1-2):305-11. PubMed ID: 1839795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vanoxerine National Institute on Drug Abuse.
    Preti A
    Curr Opin Investig Drugs; 2000 Oct; 1(2):241-51. PubMed ID: 11249581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
    Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
    Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
    Beer B; Stark J; Krieter P; Czobor P; Beer G; Lippa A; Skolnick P
    J Clin Pharmacol; 2004 Dec; 44(12):1360-7. PubMed ID: 15545306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
    Miceli JJ; Wilner KD; Hansen RA; Johnson AC; Apseloff G; Gerber N
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):5S-13S. PubMed ID: 10771448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A; Wang-Smith L; Pham T; Laliberte K
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
    Muirhead GJ; Faulkner S; Harness JA; Taubel J
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
    Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
    Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.